Amicus Therapeutics – A Biopharmaceutical Firm Based in New Jersey

Amicus Therapeutics is a biopharmaceutical firm based in New Jersey, America. The firm went public in 2007 under the trading name, NASDAQ (Google Finance). The establishment of Amicus Therapeutics was financed by selected capital venture firms such as Radius Venture, New Enterprise Associates, and Canaan Partners. The organization focuses on the treatment of rare and orphan diseases, more so lysosomal storage disorders. The product development of the company is primarily based on CHART (Chaperone-Advanced Replacement Therapy), as well as enzyme replacement therapies.
In 2014, Amicus Therapeutics was noted as one of the companies that have the broadest portfolio of pharmacological chaperones small molecule in the pharmaceutical industry. Moreover, Amicus Therapeutics has a robust development pipeline for the treatment of various human genetic disease. For example, Amicus Therapeutics has a lead product known as migalastat. The product is a personalized medicine that is used for treating people with Fabry disease. Amicus Therapeutics is also working in collaboration with JCR Pharmaceutical and GlaxoSmithKline to explore coformulation with the recombinant alpha-galactosidase. However, the collaboration lasted for only three years.
Amicus does not have the manufacturing capability to produce its products. It relies on contracts from other companies for the manufacturing process. However, in 2008, the company expanded its operation. Apart from the normal research site in New Jersey, Amicus Therapeutics also has another research site in San Diego. Since its establishment, Amicus has been on the good side of the business. In 2010, Amicus Therapeutics received a grant worth $500000 from Michael Joseph Fox Foundation. The grant was meant to support the research study that was being conducted by Amicus in partnership with David Geffen Medical School. The company also received another grant worth $210300 from ADDF (Alzheimer’s Drug Discovery Foundation). Amicus Therapeutics used the grant to support its pre-clinical work. Also, in 2013, Amicus was able to have the necessary intellectual property and proprietary materials for the treatment of Pompe infection.

For more information visit:

| Twitter


Millionaire Hedge Fund Manager Raises Money for Autism Research

British born millionaire hedge fund manager Sanjay Shah has started a unique project to raise money for autism research around the globe. Autism Rocks was founded in 2014 by Shah, with the idea of incorporating Sanjay’s passion for music with an aim to better understand his four year old son Nikhil’s autism. To achieve this, live concerts are held in conjunction with the charity in order to raise money for research, and have featured many famous artists, including Lenny Kravitz, Drake, and Michael Bublè among others.

Shah’s main objective in raising money for research is not ultimately to find a cure he says, but instead to, “better understand the ‘condition’ so I can better understand Nikhil and how he may be thinking: the only way I can do that is via research”. So far Autism Rocks has fifteen ongoing long term research projects that are focusing all their resources on finding methods to identify as early as possible who will develop autism, and then in turn to evaluate specific interventions and support that will be effective in aiding them throughout the rest of their lives. All funds raised from the concerts go to the Autism Research Trust (ART), which in turn supports the Autism Research Centre (ARC) that is based at Cambridge University, which has been working tirelessly to better understand the cause and effects of autism.

Sanjay Shah is the founder of a company called Vistex, and currently serves as the CEO and Chief Architect of the company. Before founding Vistex, Mr. Shah worked for six years as a Platinum Consultant and Logistics Developer with SAP America and SAP AG, Germany. During his time as a consultant, he contributed to over 80 SAP projects, gaining him invaluable experience. He also holds a Bachelor’s degree in Accounting and an MBA in Finance.